Summary
BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also developing Renevia facial aesthetics product, a potential treatment for facial lipoatrophy; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccines; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. BioTime’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. Its products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.
BioTime Inc (BTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
BioTime Inc, Medical Devices Deals, 2011 to YTD 2017 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
BioTime Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 15
Venture Financing 17
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 17
Partnerships 17
BioTime and Hepregen Form Joint Venture 17
Asterias Biotherapeutics Enters into Agreement with Cell Therapy Catapult 18
BioTime Forms Joint Venture With XenneX 19
Licensing Agreements 20
BioTime Enters into Licensing Agreement with Hadassah Medical 20
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 21
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 21
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 22
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 23
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 26
Biotime Amends Licensing Agreement With University of Utah 27
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 28
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 28
BioTime Enters Into Licensing Agreement With Cornell University 29
Equity Offering 30
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 30
BioTime to Raise up to USD25 Million in Private Placement of Shares 32
Asterias Biotherapeutics to Raise up to USD25 Million in Public Offering of Shares 33
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 34
BioTime Raises USD20 Million in Public Offering of Shares 35
OncoCyte Raises USD7.3 Million in Private Placement of Units 36
OncoCyte Raises USD3.2 Million in Private Placement of Units 38
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 39
Asterias Biotherapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD20 Million 40
BioTime Raises USD5 Million in Private Placement of Shares 41
BioTime Raises USD20.4 Million in Private Placement of Shares 43
BioTime Raises USD8.6 Million in Private Placement of Shares 44
Asterias Biotherapeutics Announces Private Placement of shares for USD17.5 Million upon Exercise of Warrants 45
Asterias Biotherapeutics Completes Private Placement of Shares for USD11.7 Million upon Exercise of Warrants 46
Asterias Biotherapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 47
Asterias Biotherapeutics Raises USD4 Million in Private Placement of Shares 48
Asterias Biotherapeutics Raises USD1.5 Million in Public Offering of Shares 49
BioTime Raises USD29 Million in Private Placement of Shares 50
BioTime Completes Private Placement Of Shares For US$6.4 Million 51
BioTime Announces Public Offering Of Shares For Up To US$15 Million 52
BioTime Completes Public Offering Of Shares For US$3.5 Million 53
Asterias Biotherapeutics Files Registration Statement For Public Offering Of Units For Up To US$15 Million 54
BioTime Completes Private Placement Of Units For US$9 Million 55
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 56
BioTime Announces Private Placement Of Common Stock 57
OncoCyte Completes Private Placement Of Shares For US$10 Million 58
BioTime Completes Private Placement For US$3.6 Million 59
Embryome Sciences Completes Private Placement Of US$2.5 Million 60
Acquisition 61
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 61
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 62
OrthoCyte Completes Acquisition Of Glycosan BioSystems 63
BioTime Acquires Cell Targeting 64
BioTime Inc - Key Competitors 66
Key Employees 67
Locations And Subsidiaries 68
Head Office 68
Other Locations & Subsidiaries 68
Recent Developments 70
Strategy And Business Planning 70
Apr 06, 2017: BioTime Forms New Subsidiary AgeX Therapeutics to Develop its Programs Focused on Human Aging 70
Financial Announcements 71
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 71
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 73
Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 76
Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments 78
May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 80
Other Significant Developments 83
Jun 19, 2017: Biotime Expands & Advances Ophthalmology Portfolio 83
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84
List of Tables
BioTime Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
BioTime Inc, Deals By Therapy Area, 2011 to YTD 2017 10
BioTime Inc, Medical Devices Deals, 2011 to YTD 2017 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
BioTime Completes Acquisition Of Stem Cell Assets From Geron 15
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 17
BioTime and Hepregen Form Joint Venture 17
Asterias Biotherapeutics Enters into Agreement with Cell Therapy Catapult 18
BioTime Forms Joint Venture With XenneX 19
BioTime Enters into Licensing Agreement with Hadassah Medical 20
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 21
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 21
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 22
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 23
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 26
Biotime Amends Licensing Agreement With University of Utah 27
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 28
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 28
BioTime Enters Into Licensing Agreement With Cornell University 29
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 30
BioTime to Raise up to USD25 Million in Private Placement of Shares 32
Asterias Biotherapeutics to Raise up to USD25 Million in Public Offering of Shares 33
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 34
BioTime Raises USD20 Million in Public Offering of Shares 35
OncoCyte Raises USD7.3 Million in Private Placement of Units 36
OncoCyte Raises USD3.2 Million in Private Placement of Units 38
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 39
Asterias Biotherapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD20 Million 40
BioTime Raises USD5 Million in Private Placement of Shares 41
BioTime Raises USD20.4 Million in Private Placement of Shares 43
BioTime Raises USD8.6 Million in Private Placement of Shares 44
Asterias Biotherapeutics Announces Private Placement of shares for USD17.5 Million upon Exercise of Warrants 45
Asterias Biotherapeutics Completes Private Placement of Shares for USD11.7 Million upon Exercise of Warrants 46
Asterias Biotherapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 47
Asterias Biotherapeutics Raises USD4 Million in Private Placement of Shares 48
Asterias Biotherapeutics Raises USD1.5 Million in Public Offering of Shares 49
BioTime Raises USD29 Million in Private Placement of Shares 50
BioTime Completes Private Placement Of Shares For US$6.4 Million 51
BioTime Announces Public Offering Of Shares For Up To US$15 Million 52
BioTime Completes Public Offering Of Shares For US$3.5 Million 53
Asterias Biotherapeutics Files Registration Statement For Public Offering Of Units For Up To US$15 Million 54
BioTime Completes Private Placement Of Units For US$9 Million 55
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 56
BioTime Announces Private Placement Of Common Stock 57
OncoCyte Completes Private Placement Of Shares For US$10 Million 58
BioTime Completes Private Placement For US$3.6 Million 59
Embryome Sciences Completes Private Placement Of US$2.5 Million 60
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 61
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 62
OrthoCyte Completes Acquisition Of Glycosan BioSystems 63
BioTime Acquires Cell Targeting 64
BioTime Inc, Key Competitors 66
BioTime Inc, Key Employees 67
BioTime Inc, Subsidiaries 68List of Figures
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
BioTime Inc, Medical Devices Deals, 2011 to YTD 2017 11
